In metastatic breast cancer, decreased expression of FCRL2 mRNA was observed in brain metastatic tissues compared to primary breast tumors, and its expression in primary tumors was correlated with patient survival [52]. This evidence concerns the gene FCRL2 and breast neoplasm.